Find the Perfect Plan for Your Investment Journey
Latest price
52 Week Range
$6.36 - $47.45
Next Earnings Date
May 01 2025
Next Earnings Date
May 01 2025
Latest price
Market Cap | $1.22B |
EV | $601.17M |
Shares Outstanding | 113.12M |
Beta | 1.21 |
Analyst Rating | OUTPERFORM |
Analyst Target Price | $47.86 |
P/E 2025E | - |
P/Revenue 2025E | - |
Revenue | - |
EPS | -4.80% |
Operating Cash Flow | -34.70% |
Free Cash Flow | -33.80% |
Revenue | - |
EPS | 4.50% |
Operating Cash Flow | -9.10% |
Free Cash Flow | -2.00% |
Gross Margin 2025E | - |
Net Profit Margin 2025E | - |
ROE 2025E | -70.93% |
ROCE 2024 | -88.03% |
DPS 2025E | - |
Payout Ratio 2025E | - |
Div. Yield 2025E | - |
DPS Last 3Y CAGR | - |
Price
%
1M
3M
6M
1Y
3Y
5Y
Dyne Therapeutics, Inc.
DYN
Sector
Healthcare
Industry
Biotechnology
CEO
Cox, John
Employees
191
Website
www.dyne-tx.comIPO Date
2020-09-17
Headquarters
1560 Trapelo Road, Waltham, Massachusetts, 02451, United States
COMPANY
NEWSLETTER
© Copyright 2025, All Rights Reserved